The primary objective of this study was to evaluate the prognostic significance of CD47, CD68, and CD163 expression levels, identified as TAM biomarkers, on the survival outcomes of patients with stage II-IVB NPC. This evidence concerns the gene CD47 and nasopharyngeal carcinoma.